Estradiol transdermal

FDA label

Read the full label on DailyMed ↗

Renal Undefined

Hepatic Contraindicated in hepatic impairment or disease

Instructions

• Apply patch to clean, dry lower abdomen (below umbilicus) or upper quadrant of buttock; not on or near the breasts
• Rotate application sites with ≥1 week between applications to the same site; press firmly ~10 seconds
• Wear only one system at a time during the 7-day interval
• In women with a uterus, add a progestogen to reduce endometrial cancer risk
• Use lowest effective dose; attempt to taper/discontinue at 3-6 month intervals

Available strengths

• patch 0.014, 0.025, 0.0375, 0.05, 0.06, 0.075, 0.1 mg/24 hr
• tab 10 mcg
• tab 0.5, 1, 2 mg
• cream 0.01 %
• gel 0.06, 0.1 %
• insert 4, 10 mcg
• insert 0.0075, 0.05, 0.1 mg/24 hr
• ring 0.05, 0.1 mg/d
• + 2 other marketed forms not shown

Contraindications

• Undiagnosed abnormal genital bleeding
• Breast cancer or history of breast cancer
• Estrogen-dependent neoplasia
• Active or prior DVT or pulmonary embolism
• Active or prior arterial thromboembolic disease (e.g., stroke, MI)
• Hepatic impairment or disease
• Protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders

Cautions

• Increased risk of gallbladder disease
• Discontinue if severe hypercalcemia, loss of vision (retinal vascular thrombosis), severe hypertriglyceridemia/pancreatitis, or cholestatic jaundice
• May exacerbate hypothyroidism (monitor thyroid function on replacement), fluid retention, hereditary angioedema, asthma, diabetes, epilepsy, migraine, porphyria, SLE
• Add progestogen if uterus intact (endometrial protection)

Adverse reactions

• Breast pain
• Upper respiratory tract infection
• Headache
• Abdominal pain
• Pain
• Edema
• Depression
• Pruritus (application-related)

Pregnancy Not indicated for use in pregnancy

Lactation Estrogens present in human milk and can reduce milk production